Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A SINGLE ARM, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF ORALLY ADMINISTERED TAFAMIDIS MEGLUMINE IN TRANSTHYRETIN AMYLOID POLYNEUROPATHY PARTICIPANTS IN CHINA

NCT04828993 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04828993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04828993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A SINGLE ARM, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF ORALLY ADMINISTERED TAFAMIDIS MEGLUMINE IN TRANSTHYRETIN AMYLOID POLYNEUROPATHY PARTICIPANTS IN CHINA
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
April 28, 2021
Completion date
February 12, 2023
Enrollment
15 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

transthyretin amyloid polyneuropathy (attr-pn)